News from onclive.comFollowNews from onclive.comYour destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today.We’ve aggregated 964 of onclive.com’s headlines and news stories over the past 3 months. onclive.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow Your destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today. We’ve aggregated 964 of onclive.com’s headlines and news stories over the past 3 months. onclive.com’s media bias is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about onclive.comWhere is onclive.com located?onclive.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top onclive.com NewsFDA · United StatesFDA Approves First Menin Inhibitor for Acute LeukemiaCoverage: 2 sourcesThe FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older withSee the StoryFDA · United StatesAutolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) - Autolus Therapeutics (NASDAQ:AUTL)100% Center coverage: 2 sourcesAUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy) Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL Conference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeu…See the StoryCurium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer100% Right coverage: 1 sourcesST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T (INN: lutetium (177Lu) zadavotide guraxetan) versus hormone therapy in patients with metastatic castration-resistant prostate cancer.See the StoryLatest News StoriesTopics Most Covered by onclive.comBreast CancerCancerFDAEuropean UnionMerckBreast CancerCancerFDASources Covering Similar Topicstargetedonc.comcancernetwork.comPharmacy Timesstocktitan.netpipelinereviewtargetedonc.comcancernetwork.comPharmacy TimesSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
